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11.1 Introduction 
Local hormones or autocoids are chemical mediators that are secreted by one group of cells 
to affect the function of other nearby cells. This eChapter covers a diverse range of these 
mediators, their physiological effects, pathological implications and clinical use of drugs and 
other agents that target these systems. 
 
11.2 Eicosanoids 
The eicosanoids are all the mediators derived from arachidonic acid. These include the 
prostanoids (PGF2α, PGD2, PGE2, prostacyclin (PGI2), thromboxane), and leukotrienes. 
They are involved in the control of many systems, mainly in inflammation and immunity, and 
as messengers in the central nervous system. 
 
11.2.1 Synthesis, receptors and actions 
When phospholipase A2 is activated, arachidonic acid is released from the cell membrane. 
 
Prostanoids, thromboxane, and leukotrienes are synthesised from arachidonic acid.  
Arachidonic acid is metabolised by cyclo-oxygenase to produce the prostaglandins, 
prostacyclin and thromboxane or by lipoxygenase to produce the leukotrienes (LTs).  The 
eicosanoids are synthesised on demand and are not stored. 
 
Cyclo-oxygenase metabolites activate specific receptors to influence a range of effects. There 
are two forms of the cyclo-oxygenase enzyme COX-1 and COX-2. COX-1 is a 
constitutively (always) expressed protein that produces prostanoids that have “house-
keeping” roles, e.g. regulation of blood flow, and gastric protection via release of 
cytoprotective mucus and inhibition of gastric acid production. They also cause uterine 
contraction in pregnancy. COX-2 is induced at sites of inflammation, and prostanoids 
produced in this setting tend to have pro-inflammatory effects e.g. hyperalgesia, 
vasodilatation, increased vascular permeability. Prostanoid receptors are G-protein coupled 
receptors (GPCRs). There are 10 prostanoid receptors which correspond to their ligand: IP1-
2 (PGI2), DP1-2 (PGD2), EP1-4 (PGE2), FP (PGF2α), TP (TXA2). 
 
Lipoxygenase metabolites are broadly divided into 2 classes, the chemotactic agent LTB4 
and the cysteinyl leukotrienes LTC4, LTD4 and LTE4, which cause bronchoconstriction 
and increase vascular permeability. Leukotrienes also act at cell surface GPCR on neutrophils 
(LTB4).  The cysteinyl-leukotrienes act at their cell-surface receptors CysLT1 and CysLT2 
on target cells to contract bronchial and vascular smooth muscle, to increase permeability of 
small blood vessels, to enhance secretion of mucus in the airway and gut, and to recruit 
leukocytes to sites of inflammation. 
 
11.2.3 Drugs that modify the arachidonic acid pathway 
Non steroidal anti-inflammatory drugs (NSAIDs) are cyclo-oxygenase inhibitors that 
prevent the production of the prostanoids from arachidonic acid.  These drugs are effective 
analgesics, anti-inflammatory agents and anti-pyretic agents. Most NSAIDs are non-specific 
and block both COX-1 and COX-2 (e.g. aspirin, ibuprofen, diclofenac), but COX-2 
selective agents (e.g. celecoxib) were developed to target COX-2 at sites of inflammation and 
thus reduce side effects.  However, these drugs may precipitate adverse cardiovascular effects 
and have limited use. Adverse effects of NSAIDs relate to inhibition of their gastro-protectant 
properties (eg PGE2 increases cytoprotective mucus secretion and decreases gastric acid 
secretion).  PGE2 mimetics (e.g. misoprostol) are used to treat peptic ulcer disease (PUD) 
and can be given with long-term NSAID use to reduce the incidence of these side effects. 
 
Paracetamol is another Other-The-Counter (OTC) pain killer that is reported to act by 
blocking COX. However it has no anti-inflammatory effects, and this is suggested to be 
because it only acts at a form of COX in the central nervous system (CNS).  Paracetamol has 
good analgesic and anti-pyretic effects. 
 
11.2.4 Drugs that act at the receptors 
PGE2 mimetics can be used to promote uterine contraction during labour or abortion. (e.g. 
misoprostol) 
 
Montelukast is a leukotriene receptor antagonist that is used in the prevention of asthma. 
 
11.2.5 Drugs that inhibit phospholipase A2  
Steroid anti-inflammatory drugs act by inhibiting phospholipase A2 and the release of 
arachidonic acid from the cell membrane. They have the additional action of inhibiting 
expression of COX. These are the most powerful anti-inflammatory agents available and 
are used to treat a range of serious inflammatory disorders including arthritis, asthma, 
Crohn’s disease, ulcerative colitis, psoriasis, eczema and others. (e.g. hydrocortisone, 
methylprednisolone, budesonide, beclamethosone) 
 11.3 Cytokines 
Cytokines are a diverse class of small cell signalling molecules secreted by immune cells. 
They include interleukins (ILs), which broadly target leukocytes (e.g. IL-1), and interferons 
(IFN), which are anti-viral and anti-tumour agents (e.g. IFNα, IFNβ. IFNγ). Colony 
stimulating factors, which stimulate the formation of leukocytes and tumour necrosis 
factors (TNF), which affect growth and development of cells (e.g. TNFa). 
 
The cytokines can be broadly sub-classified into pro-inflammatory and anti-inflammatory 
by the way they affect the inflammatory cascade. In most cases cytokines can amplify 
responses of other cytokines or alter expression of other cytokine receptors. The signalling is 
complex, given the variety of mediators and targets involved. 
 
11.3.1 Synthesis, receptors and actions 
Cytokines are protein, peptide or glycoprotein molecules synthesised by many immune cells.  
Cytokines activate cell-surface receptors to initiate intracellular signalling cascades that alter 
cell function.  
 
11.3.2 Drugs that modify the cytokine pathways 
Anakinra is a recombinant IL-1 receptor antagonist.  It is a recombinant form of the 
endogenous IL-1 antagonist, which supresses inflammatory cascades.  It is used to treat 
severe rheumatoid arthritis. 
 
The interferons bind to receptors on cell infected by viruses and are used to treat viral 
infections like hepatitis. They also have additional anti-tumour activity and are used to treat 
leukaemia and lymphoma (IFNα).  
 
The colony stimulating factors are recombinant stem cell factors used to stimulate growth of 
blood cell precursors. They are used to treat chemotherapy induced neutropenia and in bone 
marrow transplants (e.g. filgrastim). 
 
Monoclonal antibodies to TNFα bind to TNFα and inhibit its activity. They are used in 
autoimmune diseases such as rheumatoid arthritis and Crohn’s disease. (e.g. etanercept, 
infliximab). 
 
Drugs that modify the cytokines and/or lymphocytes (white cells) are used as 
immunosuppressants in organ transplant. These include a few different targets; 
monoclonal antibody against IL-2 (e.g. basiliximab), monoclonal antibody against the T 
lymphocyte CD3 (e.g. muromonab CD3) and anti-thymocyte globulins that remove 
leukocytes from the circulation (anti-thymocyte globulins) are all used to prevent renal 
transplant rejection. 
 
Drugs that modify the cytokines and/or lymphocytes are used in treating multiple sclerosis.  
These drugs include glatiramer which blocks T lymphocyte recognition of myelin as an 
antigen, interferon β, which reduces cytokine release, while also augmenting suppressor T-
cell function and natalizumab which is thought to inhibit leukocyte migration from blood to 
CNS, reducing the inflammation and demyelination of nerves. 
 11.4 Histamine 
Histamine is involved in both acute inflammation and immediate hypersensitivity reactions, 
is a physiological regulator of gastrointestinal tract function and also acts as a 
neurotransmitter in the central nervous system. 
 
11.4.1 Synthesis, receptors and actions 
Histamine is found in virtually all tissues in the body.  It is synthesised from the precursor 
amino acid histidine via histidine decarboxylase. Once synthesised it is stored in granules in 
mast cells, basophils and enterochromafin-like cells in the gastric fundus. It is also 
synthesised in brain as a neurotransmitter. 
 
Mast and basophil histamine is released in response to exposure to antigens and venoms, and 
toxins also elicit release of histamine, for example in the insect bites. Histamine released 
from gastric cells by cholinergic stimulation and by other stimulants (e.g. gastrin) cause 
gastric acid secretion. Morphine can also cause release of histamine from mast cells and 
histamine allergic reactions are common with the use of many drugs. Once released, 
histamine is metabolised quickly and excreted. 
 
Histamine acts on specific histamine receptors, denoted H1-H4 which are all G-protein 
coupled receptors (GPCR).  Histamine H1 receptors are present on smooth muscle 
(bronchoconstriction, uterine and GIT smooth muscle contraction), endothelium (increase 
vascular permeability), CNS (motion sickness).  Allergic rhinitis is mediated via H1 
receptors, as histamine acting on these receptors causes itching (sensory nerves), mucus 
secretion (submucosal glands), vasodilatation and oedema (vascular smooth muscle and 
endothelium). 
 
Histamine H2 receptors are present on gastric parietal cells (acid secretion) and vascular 
smooth muscle cells (vasodilatation).  Histamine H3 receptors are found in the central 
nervous system.  Histamine H4 receptors are found on many cell types and are thought to be 
involved in chemotaxis. 
 
11.4.2 Drugs that modify the actions of histamine 
H1 receptor antagonists are also widely used for allergic conditions (rhinitis, hives, insect 
bites). New generation H1 antagonists are peripherally acting and therefore less sedative than 
older antihistamines that cross the blood-brain barrier (e.g. cetirizine). Histamine release 
inhibitors (e.g. cromogylcate) can be used to prevent allergic reactions asthma. These drugs 
inhibit the release of histamine from mast cells, and therefore reduce histamine-induced 
allergy and bronchoconstriction. 
 
H1 receptor antagonists that act at the vestibular apparatus in the central nervous system are 
useful as anti-emetics and for motion sickness (e.g. promethazine), and as sedatives and for 
motion sickness (e.g. diphenhydramine). Some of the H1-receptor antagonists also have 
some anti-cholinergic activity which also contributes to this effect. 
 
H2 receptor antagonists are effective in reducing acid secretion in the stomach and are used 
to treat peptic ulcer disease (PUD) and gastro-oesphageal reflux disorder (GORD) (e.g. 
ranitidine). 
 11.5 5-Hydroxytryptamine (Serotonin) 
5-Hydroxytrypatmine (5-HT) is also known as serotonin and is a widely distributed 
monoamine neurotransmitter. 
 
11.5.1 Synthesis, receptors and actions 
5-HT is synthesised from the precursor tryptophan, an essential amino acid. Synthesised 5-
HT is stored in granules which are released via exocytosis. Main storage sites include 
enterochromaffin cells (stomach and small intestine) and neurons both in the gastrointestinal 
tract (GIT) and central nervous system (CNS) in the raphe nucleus which is involved in the 
regulation of mood, appetite and sleep.  5-HT is actively transported into platelets (which do 
not synthesise 5-HT), then released upon platelet activation to induce vasoconstriction and 
assist haemostasis.  
 
There are many subtypes of 5HT receptors, denoted 5-HT1-7, all are GPCR except for 5-HT3 
which is a ligand-gated Na
+
-K
+
 channel. Many are sub-classified further.  The effects of 5-
HT include actions within the CNS leading to behavioural effects (sleep, anxiety, feeding) 
and excitation, constriction of cerebral blood vessels, contraction of GIT smooth muscle, 
gastric motility and peristalsis, centrally and peripherally-mediated emesis. 
 
11.5.2 Drugs that modify the actions of 5-HT  
Selective serotonin re-uptake inhibitors (SSRI) are an important class of anti-depressants 
with additional anxiolytic properties. They prevent reuptake of 5-HT into the nerve terminal, 
thereby prolonging 5-HT effects (e.g. fluoxetine). 
 
5-HT2 receptor antagonism is associated with some anti-psychotic effects (e.g. atypical anti-
psychotics such as clozapine and some older generation typical anti-psychotics e.g. 
chlorpromazine).  However, blockade of 5-HT receptors alone does not give an anti-
psychotic effect. 
 
5-HT3 receptor antagonists are excellent anti-emetic agents, blocking the receptors in the 
gastrointestinal tract as well as at the chemoreceptor trigger zone.  They are particularly 
useful in treating nausea and vomiting associated with cancer chemotherapy and 
radiotherapy. (eg Setrons: ondansetron) 
 
In migraine, 3 classes of drugs used to treat migraine all act on serotonergic transmission. 
The ergot alkaloids (ergotamine) and Triptans (e.g. sumatriptan) act via 5-HT1B/1D 
receptors to elicit cerebral vasoconstriction as do 5-HT2 receptor antagonists (e.g. pizotifen). 
 
11.6 Nitric Oxide 
Nitric oxide (NO) is a biological gas that is involved in a range of cell signalling events, 
including vascular regulation, neurotransmission and regulation of inflammation.  NO 
activates soluble guanylate cyclase (sGC) to produce the second messenger cGMP, resulting 
in activation of a cascade of events leading to vasorelaxation.  
 
Nitrovasodilators are drugs that donate NO, which then elicits vasodilation. They are used to 
treat angina and heart failure associated with acute myocardial infarction (glyceryl trinitrate 
and isosorbide dinitrate) 
 
Drugs used in the treatment of erectile dysfunction inhibit phosphodiesterase (PDE), which 
breaks down cGMP, effectively prolonging the vasodilator action of cGMP. PDEV is 
preferentially located in the corpus cavenosum, thus inhibitors of this enzyme enhance and 
prolong penile erection (e.g. sildenafil).  
 
11.7 Endothelin  
Endothelin is a peptide mediators released from the endothelial cells that line the lumen of 
blood vessels. Release of endothelin is stimulated by hormones and also by mechanical 
factors, such as shear stress on the blood vessel lumen.  Endothelin acts at GPCR denoted 
ETA and ETB. It is a potent vasoconstrictor and has mitogenic activities involved in the 
remodelling of the vasculature following injury or during the progression of atherosclerosis.  
The endothelin receptor antagonist bosentan is used in pulmonary hypertension. 
 
 
